NCT02351908View on ClinicalTrials.gov

Renal Integrase Study

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2017

Conditions
HIV
Interventions
DRUG

Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)

DRUG

Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet

DRUG

Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)

Trial Locations (1)

SW10 9NH

SSAT Clinical Research Facility, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

St Stephens Aids Trust

OTHER

NCT02351908 - Renal Integrase Study | Biotech Hunter | Biotech Hunter